Allergan plc (NYSE:AGN) [Trend Analysis] retains strong position in active trade, as shares scoring -0.12% to $215.30 in a active trade session, while looking at the shares volume, around 1.03 Million shares have changed hands in this session. Allergan plc (AGN) along with Medicines360, a nonprofit global women’s health pharmaceutical company, said that the U.S. Food and Drug Administration has accepted for filing Allergan’s supplemental New Drug Application or sNDA for Liletta 52 mg.
The application seeks to potentially extend the duration of use for the prevention of pregnancy from up to three years to up to four years for Liletta, or levonorgestrel-releasing intrauterine system 52 mg. The supplement currently being reviewed by FDA includes additional efficacy and safety data from an ongoing U.S.-based Phase 3 hormonal IUD trial, ACCESS IUS, with 1,751 women receiving Liletta. The firm has institutional ownership of 88.40%, while insider ownership included 0.10%. AGN attains analyst recommendation of 2.00 with week’s performance of 7.52%. Investors looking further ahead will note that the Price to next year’s EPS is 19.67%.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -0.90% to 15.43 with around 2.04 Million shares have changed hands in this session. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) reported that the Board of Directors has elected Richard (Dick) U. DeSchutter to serve as a director, effective January 2, 2017. With the addition of Mr. DeSchutter, Valeant has surged the size of its Board to 13 members, 12 of whom are independent.
“We are delighted to welcome Dick to our board of directors,” said Joseph C. Papa, Chairman and CEO of Valeant. “His track record of pharmaceutical company leadership combined with his operational and financial advisory experience make him an ideal addition to our board. We look forward to his strategic insights as we reposition and reinvigorate the company in 2017.” The stock is going forward its fifty-two week low with 18.69% and lagging behind from its 52-week high price with -85.43%.
Similar, the positive performance for the quarter recorded as -34.41% and for the year was -84.56%, while the YTD performance remained at 7.23%. VRX has Average True Range for 14 days of 0.74.